Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

FTSE slides after BOE meeting as pound pops higher

share with twitter share with LinkedIn share with facebook
share via e-mail
02/08/2018 | 06:08pm CEST
A worker shelters from the rain as he passes the London Stock Exchange in London

MILAN/LONDON (Reuters) - The UK's top share index fell on Thursday after the Bank of England raised the prospect of higher interest rates, sending the pound higher which weighed on big British overseas earners.

The FTSE <.FTSE> was closed 1.5 percent lower at 7,170.69 points. The index is down 6.7 percent in the year to date, making it the worst performer among top European bourses.

The Bank of England said that interest rates probably need to rise sooner and by a bit more than it thought only three months ago, which boosted sterling.

The rise in the currency weighed on the FTSE's predominantly dollar-earning firms, with shares in heavyweight consumer staples British American Tobacco (>> British American Tobacco), Reckitt Benckiser (>> Reckitt Benckiser) and Unilever (>> Unilever) dropping 1.8 percent to 3.2 percent.

"We are growing cautious on those companies which rely heavily on overseas earnings, as rising interest rates could cause the pound to strengthen further from here," Andrew Morgan, portfolio manager of Alpha:r² at Walker Crips, said.

"We continue to be relatively defensively positioned in equities, despite the recent dip, and are looking at certain sectors - such as Financials - which tend to benefit from a rising interest rate environment," Morgan added.

On the day shares in banking stocks RBS (>> Royal Bank of Scotland Group), Barclays (>> Barclays) and Lloyds (>> Lloyds Banking Group) were among the dozen or so stocks in positive territory, up 0.4 percent to 1 percent.

GlaxoSmithKline (>> GlaxoSmithKline) was another riser, up 1.4 percent after U.S. regulators delayed approval of a generic copy from Novartis of its blockbuster Advair lung drug and after the group took legal action against Gilead Sciences (>> Gilead Sciences) over a new HIV drug.

The news helped build confidence after an upbeat results presentation by GlaxoSmithKline on Wednesday. Competitive threats to its respiratory and HIV businesses are seen as key risks for the company's stock.

AstraZeneca (>> AstraZeneca) rose 1.2 percent, boosted by a price target upgrade from Berenberg.

WPP (>> WPP Group) rose 3.1 percent following a reassuring update from French peer Publicis (>> Publicis Groupe), while Compass (>> Compass Group plc), the world's biggest catering firm, jumped more than 5 percent after it raised its expectations for revenue growth.

Their gains however were more than offset by broad-based weakness as markets remained nervous following a sell-off earlier this week triggered by a spike in global yields and volatility.

Miners, along with energy stocks, were a big weight on the FTSE, with the two commodities-related sectors collectively wiping around 40 points off the index, as prices of copper <CMCU3> and other metals fell and oil retreated.

Precious metals miner Randgold (>> Randgold Resources) fell 2.4 percent after HSBC raised its rating on the stock but trimmed its price target. Antofagasta (>> Antofagasta) and BHP Billiton (>> BHP Billiton Plc) were also both down around 2.5 percent.

Among midcaps, Sophos (>> Sophos Ltd) fell 17.5 percent after the cloud services provider reported slower growth in the amount it bills its customers, while TalkTalk (>> TalkTalk Telecom Group) slumped after flagging a dividend cut and a cash call.

(Reporting by Danilo Masoni and Kit Rees; Editing by Peter Graff)

By Danilo Masoni and Kit Rees

Stocks mentioned in the article
ChangeLast1st jan.
ANTOFAGASTA -0.66% 1054.5 Delayed Quote.4.93%
BARCLAYS 0.44% 206.2 Delayed Quote.1.53%
BHP BILLITON PLC -1.10% 1695.2 Delayed Quote.11.34%
BRITISH AMERICAN TOBACCO 1.82% 3869 Delayed Quote.-22.90%
COMPASS GROUP PLC 1.27% 1630 Delayed Quote.1.88%
GILEAD SCIENCES -0.22% 67.38 Delayed Quote.-5.60%
GLAXOSMITHKLINE 0.39% 1500 Delayed Quote.13.42%
LLOYDS BANKING GROUP -0.50% 65.67 Delayed Quote.-3.51%
PUBLICIS GROUPE 0.93% 60.66 Real-time Quote.7.08%
RANDGOLD RESOURCES -0.66% 5758 Delayed Quote.-22.29%
RECKITT BENCKISER 0.79% 6028 Delayed Quote.-12.88%
ROYAL BANK OF SCOTLAND GROUP -0.17% 289.7 Delayed Quote.4.21%
SOPHOS GROUP PLC 1.57% 583 Delayed Quote.2.28%
TALKTALK TELECOM GROUP -1.32% 119.4 Delayed Quote.-20.14%
UNILEVER 0.31% 4182.5 Delayed Quote.1.70%
UNILEVER (NL) 0.46% 48.205 Delayed Quote.2.66%
WPP GROUP 0.35% 1277.5 Delayed Quote.-4.74%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
05/26ASTRAZENECA : reaches another milestone with Imfinzi trial
05/26ASTRAZENECA : Success for AstraZeneca after lung cancer treatment improves survi..
05/26ASTRAZENECA : expands alliance with Bicycle Therapeutics
05/25ASTRAZENECA : Study Data from AstraZeneca Provide New Insights into Breast Cance..
05/25ASTRAZENECA : Investigators at AstraZeneca Describe Findings in Catheterization ..
05/25ASTRAZENECA : Emulate, Inc. and AstraZeneca Form Strategic Agreement to Work Sid..
05/25ASTRAZENECA : Researchers from AstraZeneca Provide Details of New Studies and Fi..
05/25ASTRAZENECA : Reports on Antidiabetic Agents from AstraZeneca Provide New Insigh..
05/25INVESTIGATORS AT ASTRAZENECA ZERO IN : Is it the Dawn of a New Beginning?)
05/25ASTRAZENECA : IMFINZI® (Durvalumab) Significantly Improves Overall Survival in t..
More news
News from SeekingAlpha
05/273 THINGS IN BIOTECH, MAY 26 : Immunotherapy Strikes Lung Cancer Yet Again 
05/26MINING ASCO 2018'S GOLD, PART 4 : Radiation Glows In Breast And Brain 
05/25WALL STREET BREAKFAST, MAY 25TH : EU Data Privacy Rules Take Effect; U.S. And Ch.. 
05/25AstraZeneca's Imfinzi successful in late-state lung cancer study 
05/25WALL STREET BREAKFAST : New Privacy Bar With GDPR 
Financials ($)
Sales 2018 22 463 M
EBIT 2018 5 422 M
Net income 2018 1 899 M
Debt 2018 14 637 M
Yield 2018 3,77%
P/E ratio 2018 39,02
P/E ratio 2019 30,84
EV / Sales 2018 4,78x
EV / Sales 2019 4,50x
Capitalization 92 832 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 74,4 $
Spread / Average Target 2,1%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA5.99%92 832
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708